RHO GER Week ended 31 Jul 2026

Weekly Investor Report

Roche Holding AG · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 388.2 EUR
0.1% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 5.0% above the Trend Line and sits at 85.8% of its 52-week range. The latest completed week returned 0.1%, after a 3.6% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 50/100.

Setup score 71 out of 100
Latest Close 388.2 EUR 31 Jul 2026
1W Return 0.1% latest completed week
4W Return 3.6% short-term follow-through
12W Return 9.7% quarterly tape
Trend Breadth 84.6% 44 of 52 weeks active
Volume Ratio 1.8x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • 2 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.1% Latest completed week; four-week move 3.6%. Indicator stack 47/95 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 60.02% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 2 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 5.0% above the Trend Line and sits at 85.8% of its 52-week range. The latest completed week returned 0.1%, after a 3.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6712-week average 0.61

12-week confirmation

Trend active4/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.67Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 3.6% over four weeks, 9.7% over 12 weeks, and 39.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W0.1%
4W3.6%
12W9.7%
26W2.5%
52W39.9%
Active trend streak0 weeks
Active weeks in one year44
Trend breadth84.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.58Latest activity-pressure read.
Pressure change425.1%Four-week change in activity pressure.
Leadership7.02Latest relative-leadership reading.
RS change55.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 91% Model confidence 74%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength54/100Blend of value, momentum, and quality. Underlying universe rank 47; rank 1 is best.
Value14/100Relative valuation strength. Underlying universe rank 87; rank 1 is best.
Quality95/100Profitability and accounting quality. Underlying universe rank 6; rank 1 is best.
Momentum79/100Medium-term price momentum. Underlying universe rank 22; rank 1 is best.
Growth77/100Revenue and earnings growth. Underlying universe rank 24; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework52/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
24.0x
Price divided by trailing earnings.
Price / sales
4.9x
Market value relative to trailing revenue.
EV / EBITDA
15.7x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
73.7%
Gross profit retained from each unit of revenue.
Operating margin
29.2%
Operating profit retained from revenue.
Free-cash-flow margin
20.6%
Free cash flow generated from revenue.
Return on invested capital
22.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
1.5%
Latest one-year revenue growth.
EPS growth
55.6%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-13.3%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
3.0%
Cash dividends relative to market value.
Buyback yield
0.3%
Net share repurchases relative to market value.
Shareholder yield
3.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 2 relevant articles.

0 positive · 2 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-5.0%Distance below the 52-week high.
13-week volatility2.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+5.6%Week of 24 Jul.
Worst week-7.6%Week of 6 Mar.
Latest week+0.1%Week of 31 Jul.

Shape of recent returns

Strong gains2
Modest gains11
Flat weeks0
Modest losses11
Sharp losses2
Recent vol2.5%13-week weekly-return volatility.
Base vol3.6%52-week weekly-return volatility.
Up/down split31/21Count of positive and negative weeks in the 52-week window.
Average skew2.9% / -2.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape70/100

Trend, activity pressure, participation, and risk combine to a 70/100 tape read.

 Indicator analysis51/100

Latest 12-week confirmation: trend 4/12, activity pressure 4/12, relative leadership 12/12.

Activity pressure 0.67; 2 reversal markers Next-Week ExpectancyPositive 60.02%

Next-week expectancy is positive with a 60.02% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors60/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 36 SVQF52/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 180.5 of 372 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 2 relevant articles.

Roche Holding Ltd Revenue Breakdown – HAN:RHO Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026388.2 EUR0.1%369.9 EUR331.5 EUR0.587.022.1KOff
24 Jul 2026388.0 EUR5.6%368.8 EUR330.6 EUR0.489.712.5KOff
17 Jul 2026367.4 EUR-0.2%367.6 EUR329.7 EUR0.255.54991Off
10 Jul 2026368.0 EUR-1.8%366.9 EUR329.2 EUR0.045.161.8KOff
3 Jul 2026374.6 EUR1.1%366.0 EUR328.5 EUR-0.184.512.1KOff
26 Jun 2026370.6 EUR5.2%364.6 EUR327.8 EUR-0.528.4099Off
19 Jun 2026352.2 EUR-2.7%363.3 EUR327.1 EUR-0.682.15406Off
12 Jun 2026362.0 EUR-0.2%362.9 EUR326.6 EUR-0.656.77266Off
5 Jun 2026362.8 EUR-1.5%361.4 EUR326.0 EUR-0.686.78106On
29 May 2026368.4 EUR-0.9%358.9 EUR325.4 EUR-0.727.301.5KOn
22 May 2026371.8 EUR2.7%356.2 EUR324.6 EUR-0.799.621.3KOn
15 May 2026362.2 EUR2.3%353.7 EUR323.7 EUR-0.8511.401.5KOn
8 May 2026354.0 EUR-0.8%352.0 EUR323.0 EUR-0.867.65737On
1 May 2026356.8 EUR-0.8%350.8 EUR322.5 EUR-0.869.021.1KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.